Home LiteratureArticle Details
PMID: 16849433 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

Proceedings of the National Academy of Sciences of the United States of America ·Vol. 103 ·No. 30 ·2006-07-25 ·Pages 11405-10

Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Persaud K, Wu Y, Streilein JW, Dana R

Abstract

Transparency of the cornea, the window of the eye, is a prerequisite for vision. Angiogenesis into the normally avascular cornea is incompatible with good vision and, therefore, the cornea is one of the few tissues in the human body where avascularity is actively maintained. Here, we provide evidence for a critical mechanism contributing to corneal avascularity. VEGF receptor 3, normally present on lymphatic and proliferating blood vascular endothelium, is strongly constitutively expressed by corneal epithelium and is mechanistically responsible for suppressing inflammatory corneal angiogenesis.

MeSH Terms
Animals Cell Proliferation Epithelium, Corneal/metabolism Flow Cytometry Humans Inflammation Mice Mice, Inbred BALB C Neovascularization, Physiologic Vascular Endothelial Growth Factor C/metabolism Vascular Endothelial Growth Factor D/metabolism Vascular Endothelial Growth Factor Receptor-3/biosynthesis,chemistry Vision, Ocular
Chemicals
Vascular Endothelial Growth Factor C Vascular Endothelial Growth Factor D Vascular Endothelial Growth Factor Receptor-3
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Cursiefen Claus
Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA.
Chen Lu
Saint-Geniez Magali
Hamrah Pedram
Jin Yiping
Rashid Saadia
Pytowski Bronislaw
Persaud Kris
Wu Yan
Streilein J Wayne
Dana Reza
References (30)
30 references, click to expand
  1. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis.
    Blood. 2000 Jul 15;96(2):546-53 PMID: 10887117
  2. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo.
    Invest Ophthalmol Vis Sci. 2005 May;46(5):1647-52 PMID: 15851564
  3. Role of recipient epithelium in promoting survival of orthotopic corneal allografts in mice.
    Invest Ophthalmol Vis Sci. 2001 Mar;42(3):720-6 PMID: 11222533
  4. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization.
    Hum Gene Ther. 2001 Jul 1;12(10):1299-310 PMID: 11440623
  5. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea.
    Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8868-73 PMID: 12070340
  6. Molecular mechanisms of lymphangiogenesis in health and disease.
    Cancer Cell. 2002 Apr;1(3):219-27 PMID: 12086857
  7. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin.
    Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2127-35 PMID: 12091407
  8. Lymphangiogenesis and cancer metastasis.
    Nat Rev Cancer. 2002 Aug;2(8):573-83 PMID: 12154350
  9. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology.
    Cornea. 2003 Apr;22(3):273-81 PMID: 12658100
  10. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
    Circ Res. 2003 May 30;92(10):1098-106 PMID: 12714562
  11. Lymphangiogenesis and tumor metastasis.
    Cell Tissue Res. 2003 Oct;314(1):167-77 PMID: 12883995
  12. Ocular immune privilege: therapeutic opportunities from an experiment of nature.
    Nat Rev Immunol. 2003 Nov;3(11):879-89 PMID: 14668804
  13. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis.
    Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1117-24 PMID: 15037577
  14. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.
    J Clin Invest. 2004 Apr;113(7):1040-50 PMID: 15057311
  15. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity.
    Nat Med. 2004 Aug;10(8):813-5 PMID: 15235599
  16. The stimulus to neovascularization in the cornea.
    Exp Eye Res. 1966 Jul;5(3):168-84 PMID: 5914649
  17. Tumor growth and neovascularization: an experimental model using the rabbit cornea.
    J Natl Cancer Inst. 1974 Feb;52(2):413-27 PMID: 4816003
  18. How the field of controlled-release technology began, and its central role in the development of angiogenesis research.
    Biomaterials. 1990 Nov;11(9):615-8 PMID: 1708683
  19. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.
    Cancer Res. 1992 Oct 15;52(20):5738-43 PMID: 1327515
  20. Molecular cloning of murine FLT and FLT4.
    Oncogene. 1993 Aug;8(8):2293-8 PMID: 8393164
  21. Novel production of interleukin-1 receptor antagonist peptides in normal human cornea.
    J Clin Invest. 1995 Jan;95(1):82-8 PMID: 7814649
  22. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.
    Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3566-70 PMID: 7724599
  23. Definition of two angiogenic pathways by distinct alpha v integrins.
    Science. 1995 Dec 1;270(5241):1500-2 PMID: 7491498
  24. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas.
    Invest Ophthalmol Vis Sci. 1996 Feb;37(2):413-24 PMID: 8603847
  25. A model of angiogenesis in the mouse cornea.
    Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1625-32 PMID: 8675406
  26. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.
    Invest Ophthalmol Vis Sci. 1998 Jan;39(1):18-22 PMID: 9430540
  27. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C.
    J Biol Chem. 1998 Apr 3;273(14):8413-8 PMID: 9525952
  28. Vascular endothelial growth factor C induces angiogenesis in vivo.
    Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14389-94 PMID: 9826710
  29. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
    J Natl Cancer Inst. 2005 Jan 5;97(1):14-21 PMID: 15632376
  30. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.
    Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2514-22 PMID: 10937562
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
DOI
10.1073/pnas.0506112103
Published
2006-07-25
Epub
2006-00-18
Pages
11405-10
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC1544098
Subset
IM
Grants
NEI NIH HHS · R01 EY010765 · United States
NEI NIH HHS · R01 EY012963 · United States
NEI NIH HHS · EY10765 · United States
NEI NIH HHS · EY12963 · United States
External Links
PubMed source DOI: 10.1073/pnas.0506112103 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2